[go: up one dir, main page]

WO2004078169A8 - Use of ep2 selective receptor agonists in medical treatment - Google Patents

Use of ep2 selective receptor agonists in medical treatment

Info

Publication number
WO2004078169A8
WO2004078169A8 PCT/IB2004/000553 IB2004000553W WO2004078169A8 WO 2004078169 A8 WO2004078169 A8 WO 2004078169A8 IB 2004000553 W IB2004000553 W IB 2004000553W WO 2004078169 A8 WO2004078169 A8 WO 2004078169A8
Authority
WO
WIPO (PCT)
Prior art keywords
facilitating
treating
hypertension
selective receptor
occurrence
Prior art date
Application number
PCT/IB2004/000553
Other languages
French (fr)
Other versions
WO2004078169A1 (en
Inventor
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Original Assignee
Pfizer Prod Inc
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Alexander Angelo Constan, Prakash Raj Keshary, David Burton Maclean, Vishwas Madhav Paralkar, Doina Cosma Roman, David Duane Thompson, Timothy Michael Wright filed Critical Pfizer Prod Inc
Priority to BRPI0408061-0A priority Critical patent/BRPI0408061A/en
Priority to EP04713611A priority patent/EP1601351A1/en
Priority to CA002518193A priority patent/CA2518193A1/en
Priority to MXPA05009398A priority patent/MXPA05009398A/en
Priority to AU2004216898A priority patent/AU2004216898A1/en
Priority to NZ541828A priority patent/NZ541828A/en
Priority to JP2006506276A priority patent/JP2006519250A/en
Publication of WO2004078169A1 publication Critical patent/WO2004078169A1/en
Publication of WO2004078169A8 publication Critical patent/WO2004078169A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to methods of treating pulmonary hypertension, facilitating joint fusion, facilitating tendon and ligament repair, reducing the occurrence of secondary fracture, treating avascular necrosis, facilitating cartilage repair, facilitating bone healing after limb transplantation, facilitating liver regeneration, facilitating wound healing, reducing the occurrence of gastric ulceration, treating hypertension, facilitating the growth of tooth enamel or finger or toe nails, treating glaucoma, treating ocular hypertension, and repairing damage caused by metastatic bone disease using an EP2 selective receptor agonist.
PCT/IB2004/000553 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment WO2004078169A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BRPI0408061-0A BRPI0408061A (en) 2003-03-04 2004-02-23 medical treatment using an ep 2 selective receptor agonist
EP04713611A EP1601351A1 (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment
CA002518193A CA2518193A1 (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment
MXPA05009398A MXPA05009398A (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment.
AU2004216898A AU2004216898A1 (en) 2003-03-04 2004-02-23 Use of EP2 selective receptor agonists in medical treatment
NZ541828A NZ541828A (en) 2003-03-04 2004-02-23 Use of EP2 selective receptor agonists in medical treatment
JP2006506276A JP2006519250A (en) 2003-03-04 2004-02-23 Use of EP2 selective receptor agonists in medical procedures

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04
US60/451,889 2003-03-04

Publications (2)

Publication Number Publication Date
WO2004078169A1 WO2004078169A1 (en) 2004-09-16
WO2004078169A8 true WO2004078169A8 (en) 2005-04-21

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/000553 WO2004078169A1 (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment

Country Status (14)

Country Link
EP (1) EP1601351A1 (en)
JP (1) JP2006519250A (en)
KR (1) KR20050105511A (en)
CN (1) CN1859903A (en)
AU (1) AU2004216898A1 (en)
BR (1) BRPI0408061A (en)
CA (1) CA2518193A1 (en)
CL (1) CL2004000412A1 (en)
MX (1) MXPA05009398A (en)
NZ (1) NZ541828A (en)
PL (1) PL378748A1 (en)
TW (1) TW200424176A (en)
WO (1) WO2004078169A1 (en)
ZA (1) ZA200506532B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196089B2 (en) 2003-01-29 2007-03-27 Asterand Uk Limited EP4 receptor antagonists
US7417068B2 (en) 2003-10-16 2008-08-26 Asterand Uk Limited EP4 receptor antagonists

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070270489A1 (en) * 2003-07-25 2007-11-22 Ono Pharmaceutical Co., Ltd. Remedy for Cartilage-Related Diseases
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
CN102626517B (en) 2006-03-24 2015-07-29 儿童医疗中心有限公司 Regulate the method for hematopoietic stem cell growth
BRPI0714683A2 (en) 2006-07-28 2013-03-26 Pfizer Prod Inc ep2 agonists
RU2480213C2 (en) * 2006-10-20 2013-04-27 Чилдрен'З Медикал Сентер Корпорейшн Method for tissue regeneration stimulation
RU2522456C2 (en) * 2007-08-21 2014-07-10 Синомикс, Инк. Compounds inhibiting (blocking) bitter taste, methods for use and production thereof
WO2009113600A1 (en) * 2008-03-12 2009-09-17 宇部興産株式会社 Pyridylaminoacetic acid compound
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
US9051548B2 (en) 2009-02-03 2015-06-09 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
KR101681347B1 (en) 2009-03-30 2016-11-30 우베 고산 가부시키가이샤 Pharmaceutical composition for treating or preventing glaucoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
KR20120068902A (en) * 2009-09-11 2012-06-27 우베 고산 가부시키가이샤 Aniline compounds
JP2011057633A (en) * 2009-09-11 2011-03-24 Ube Industries Ltd Medicine containing pyridylaminoacetic acid compound
WO2011030865A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Substituted zenzyl compounds
WO2011030871A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 N-substituted heteroaryl compounds
US20120226036A1 (en) * 2009-09-11 2012-09-06 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030873A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Benzyl compounds
WO2011030872A1 (en) * 2009-09-11 2011-03-17 宇部興産株式会社 Sulfonamide compounds
AU2010336248A1 (en) * 2009-12-25 2012-08-02 Ube Industries, Ltd. Aminopyridine compound
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
IN2014CN02290A (en) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
EP2785834B1 (en) 2011-12-02 2020-09-23 Fate Therapeutics, Inc. Enhanced stem cell composition
WO2013082241A2 (en) 2011-12-02 2013-06-06 Fate Therapeutics, Inc. Improved methods of treating ischemia
HK1198514A1 (en) * 2012-01-20 2015-05-15 Acucela, Inc. Substituted heterocyclic compounds for disease treatment
WO2014078434A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
WO2014150602A1 (en) 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
MX2015013848A (en) 2013-03-28 2016-03-01 Ube Industries Substituted biaryl compound.
UY36118A (en) 2014-05-13 2016-01-08 Novartis Ag COMPOUNDS AND COMPOSITIONS TO INDUCE CONDROGENESIS
CN106397149B (en) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 The preparation method of pentafluorobenzaldehyde
CN115636761B (en) * 2021-07-20 2024-07-05 中国石油天然气股份有限公司 Oil-soluble surfactant, oil displacement agent and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
AU4881697A (en) * 1996-12-20 1998-07-17 Pfizer Inc. Prevention and treatment of skeletal disorder with EP2 receptor subtype se lective prostaglandin E2 agonists
UA67754C2 (en) * 1997-10-10 2004-07-15 Пфайзер, Інк. Prostaglandin agonists and use thereof for the treatment of bone disorders
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196089B2 (en) 2003-01-29 2007-03-27 Asterand Uk Limited EP4 receptor antagonists
US7507754B2 (en) 2003-01-29 2009-03-24 Asterand Uk Limited EP4 receptor antagonists
US7417068B2 (en) 2003-10-16 2008-08-26 Asterand Uk Limited EP4 receptor antagonists
US7569602B2 (en) 2003-10-16 2009-08-04 Asterand Uk Limited Furan derivatives as EP4 receptor antagonists

Also Published As

Publication number Publication date
CN1859903A (en) 2006-11-08
CA2518193A1 (en) 2004-09-16
EP1601351A1 (en) 2005-12-07
TW200424176A (en) 2004-11-16
CL2004000412A1 (en) 2005-02-04
WO2004078169A1 (en) 2004-09-16
ZA200506532B (en) 2007-03-28
MXPA05009398A (en) 2005-12-05
KR20050105511A (en) 2005-11-04
JP2006519250A (en) 2006-08-24
PL378748A1 (en) 2006-05-15
NZ541828A (en) 2008-06-30
AU2004216898A1 (en) 2004-09-16
BRPI0408061A (en) 2006-02-14

Similar Documents

Publication Publication Date Title
WO2004078169A8 (en) Use of ep2 selective receptor agonists in medical treatment
Pugh et al. Advances in the management of humeral nonunion
WO2007120539A3 (en) Orthopedic device
WO2001050999A3 (en) Materials and methods for improved bone tendon bone transplantation
WO2003013342A3 (en) Materials and methods for improved bone tendon bone transplantation
WO2010033702A3 (en) Intramedullary arthrodesis nail and method of use
WO2003015612A3 (en) Materials and methods to promote repair of nerve tissue
AU2118601A (en) Ankle replacement system
Masri et al. Seven specialized exposures for revision hip and knee replacement
Cottom et al. The “all-inside” arthroscopic Broström procedure with additional suture anchor augmentation: a prospective study of 45 consecutive patients
RU2006126967A (en) METHOD FOR ARTHRODESIS OF THE ANKLE AND TANTED JOINTS
BR0314362A (en) Method to prevent or reduce secondary fractures after hip fracture
Raja Gopal et al. Functional outcome of ante grade interlocking intramedullary nailing for humeral shaft fractures
KR101439944B1 (en) Tibial tuberosity advancement using hydroxyapatite scaffold in the small animal cranial cruciate ligament rupture
De Carolis et al. A lifelong story: Case report of a humeral shaft nonunion successfully treated after 30 years
RU2000103308A (en) METHOD FOR OSTEOSYNTHESIS OF INJOINT JOINT COMPRESSION FROUSERS OF TYPO condyles under the control of arthroscopy
RU2003112396A (en) METHOD FOR REHEDIATED HIP JOINT
RU2423085C2 (en) Method of endoprosthetics of hip joint in case of high congenital hip dislocation
Mathoulin et al. Scaphoid Nonunion: Surgical Fixation with Vascularized Bone Grafts–Volar Pedicle
Low et al. Herbert screw fixation of scaphoid fractures
RU2006100579A (en) METHOD FOR EXTRA-JOINT CORRECTION OF KNEE JOINT STRAINS
Ghauri et al. Simple plan of treatment for aseptic non-union of Diaphyseal Fractures of long bones
Magnan et al. Short and Long Term Results of Treatment
Beckenbaugh PIP joint surgery in rheumatoid disease
WO2004004663A3 (en) Compositions and methods for ligament growth and repair

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1-2005-501597

Country of ref document: PH

WR Later publication of a revised version of an international search report
WWE Wipo information: entry into national phase

Ref document number: 2005/06532

Country of ref document: ZA

Ref document number: 200506532

Country of ref document: ZA

Ref document number: 541828

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 170380

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2004216898

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004713611

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2518193

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/009398

Country of ref document: MX

Ref document number: 1020057016414

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006506276

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2004216898

Country of ref document: AU

Date of ref document: 20040223

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004216898

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 20048085767

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057016414

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004713611

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0408061

Country of ref document: BR